Background: The pathobiology of seborrheic dermatitis is rooted in a peculiar inflammatory reaction to Malassezia spp. Both topical corticosteroids and antifungals are routinely used with success, either singly or in combination. Objective: To assess the effect of a new combination therapy in this condition. Methods: Eighteen patients with facial seborrheic dermatitis were treated in a pilot double-blind trial with an anhydrous gel containing the combination of 2% ketoconazole and 0.05% desonide (n = 9) or the unmedicated gel (n = 9). The products were applied once daily for 3 consecutive weeks. Disease severity was assessed at the start and weekly during treatment, as well as 2, 4 and 8 weeks after the end of treatment or at the time of recurrence. The overall clinical assessments were performed using a visual analogue scale. Objective measurements included squamometry X after harvesting the stratum corneum and the erythema index yielded by narrow-band reflectance spectrophotometry. Data were evaluated in an intent-to-treat analysis. Results: The combination therapy yielded reductions in the overall clinical symptom severity of 49, 84 and 92% after 1, 2 and 3 weeks of treatment, respectively. The corresponding improvements with the placebo gel were significantly smaller (p < 0.01), reaching 23, 29 and 42% at successive 1-week intervals. At the end of the 3-week treatment, the clinical signs had completely subsided in 6/9 patients treated with the medicated gel and in only 1/9 patients using the placebo gel. Thus, the clinical response rate was significantly faster (p < 0.01) with the combination therapy than with the vehicle. Differences between the treatment groups using objective noninvasive assessments were also significantly (p < 0.01) in favor of the combination therapy. The squamometry X measurements showed 47, 67 and 74% improvements with the combination gel after 1, 2 and 3 weeks, respectively. The corresponding values with the placebo gel were 34, 46 and 53%, respectively. The erythema index was almost completely reduced to normal at week 2 of treatment in contrast with about 50% reduction with the unmedicated vehicle. None of the patients reported any side effects. Conclusion: The combination of ketoconazole with desonide in an anhydrous gel is well tolerated and proves to be significantly more effective than the vehicle for treating facial seborrheic dermatitis. The fast response to treatment and the limited additional improvement between weeks 2 and 3 of the treatment suggest that this combination product may be efficacious with once daily applications for 2 weeks. These data call for expanded studies comparing each single compound, the vehicle and the combination therapy.

1.
McGrath J, Murphy GM: The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. Drugs 1991;41:178–184.
2.
Piérard-Franchimont C, Arrese JE, Piérard GE: Immunohistochemical aspects of the link between Malassezia ovalis and seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1995;4:14–19.
3.
Hay RJ, Graham-Brown RA: Dandruff and seborrhoeic dermatitis: Causes and management. Clin Exp Dermatol 1997;22:3–6.
4.
Kesavan S, Walters CE, Holland KT, Ingham E: The effects of Malassezia on pro-inflammatory cytokine production by human peripheral blood mononuclear cells in vitro. Med Mycol 1998;36:97–106.
5.
Faergemann J: Management of seborrhoeic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000;1:75–80.
6.
Faergemann J: Seborrhoeic dermatitis and Pityrosporumorbiculare: Treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Dactacort), miconazole and hydrocortisone. Br J Dermatol 1986;38:695–700.
7.
Stratigos ID, Antoniou CH, Katsambas A, Böhler K, Fritsch P, Schmölz A, Michaelidis D, De Beule K: Ketoconazole 2% cream versus 1% hydrocortisone cream in the treatment of seborrhoeic dermatitis: A double blind comparative study. J Am Acad Dermatol 1988;19:850–853.
8.
Faergemann J: Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. Acta Derm Venereol 1990;70:171–172.
9.
Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y: Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology 1992;184:275–280.
10.
Peter RU, Richarz B, Arthauer U: Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: Results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995;132:441–445.
11.
Pari T, Pulimood S, Jacob M, George S, Jeyaseelan L, Thomas K: Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05 % clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1998;10:89–90.
12.
van’t Veen AJ, Prevoo RLMA, Velders AJ, Jagtman BA, Van Niel JCG, Stolz E: Betamethasone 17-valerate compared with ketoconazole for topical treatment of seborrhoeic dermatitis of the scalp in adults: Results of a Dutch multicenter study. J Dermatol Treat 1998;9:239–245.
13.
Piérard-Franchimont C, Hermanns JF, Degreef H, Arrese JE, Piérard GE: From axioms to new insights into dandruff. Dermatology 2000;200:93–98.
14.
Piérard-Franchimont, Piérard GE, Arrese JE, de Doncker P: Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: Clinical, squamometric and mycological assessments. Dermatology 2001;202:171–176.
15.
Piérard-Franchimont C, Willemaers V, Fraiture AL Piérard GE: Squamometry in seborrheic dermatitis. Int J Dermatol 1999;38:712–715.
16.
Beetens JR, Loots W, Somers Y, Coene MC, de Clerck F: Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol 1986;35:883–891.
17.
Van Custem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PAJ: The antiinflammatory effects of ketoconazole. J Am Acad Dermatol 1991;25:257–261.
18.
Yoshimura T, Kudoh K, Aiba S, Tagami H: Antiinflammatory effects of ketoconazole for the inflammation induced on the skin of hairless guinea-pigs by repeated applications of heat-killed spores of M. furfur: A comparative study with hydrocortisone 17-butyrate. J Dermatol Treat 1995;6:113–116.
19.
Piérard GE: EEMCO guidance for the assessment of dry skin (xerosis) and ichthyosis: Evaluation by stratum corneum strippings. Skin Res Technol 1996;2:3–11.
20.
Piérard GE: EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 1998;10:1–11.
21.
Arrese JE, Piérard Franchimont C, De Doncker P, Heremans A, Cauwenbergh G, Piérard GE: Effect of ketoconazole-medicated shampoos on squamometry and Malassezia ovalis load in pityriasis capitis. Cutis 1996;58:235–237.
22.
Piérard-Franchimont C, Henry F, Piérard GE: The SACD method and the XLRS squamometry tests revisited. Int J Cosmet Sci 2000;22:437–446.
23.
Hermanns JF, Piérard-Franchimont C, Piérard GE: Skin colour assessment in safety testing of cosmetics: An overview. Int J Cosmet Sci 2000;22:67–71.
24.
Hermanns JF, Petit L, Hermanns-Lê T, Piérard GE: Analytic quantification of phototype-related regional skin complexion. Skin Res Technol 2001;7:168–171.
25.
Faergemann J: In vitro and in vivo activities of ketoconazole and itraconazole against P. orbiculare. Antimicrob Agents Chemother 1984;26:773–778.
26.
Van Gerven F, Odds F: The anti-Malazzezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: Bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Mycoses 1995;38:389–393.
27.
Nenoff P, Haustein UF: In vitro susceptibility testing of Pityrosporum ovale against antifungal, antiseborrheic and antipsoriatic agents. J Eur Acad Dermatol Venereol 1994;3:331–333.
28.
Hammer KA, Carson CF, Riley TV: In vitro activities of ketoconazole, econazole miconazole, and Melaleuca alternifolia (tea tree) oil against Malassezia species. Antimicrob Agents Chemother 2000;44:467–469.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.